Development of a Rasch-Built Amyotrophic Lateral Sclerosis Impairment Multidomain Scale to Measure Disease Progression in ALS.
Adriaan D de JonghRuben P A van EijkLeonhard A BakkerTommy M BunteAnita BeelenConny van der MeijdenMichael A van EsJohanna M A Visser-MeilyEsther T KruitwagenJan Herman VeldinkLeonard H van den BergPublished in: Neurology (2023)
We developed the AIMS, consisting of unidimensional bulbar, motor and respiratory subscales that may characterize disease severity better than a total score. AIMS subscales have high test-retest reliability, are optimized to measure disease progression and are strongly related to survival time. The AIMS can be easily administered and may increase the likelihood of identifying effective treatments in ALS clinical trials.